Here's what I recommend.
What are the odds?
Let's check the charts for the answer.
Here's the next area for our price target.
The stock is trading higher Monday on full approval for its Covid vaccine.
The 2022 Tax Loss Selling Recovery Portfolio is holding its own despite difficult market conditions.
ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.
JNJ has been in a longer-term uptrend but that may not be enough to keep the rally going.
Let's take a look at the charts and indicators.
This health biotech has been dealt some tough hands, but is still at the table. Here's my take.